Get the Stockscreener App
42.70
0.56%
-0.24
After Hours:
42.99
0.29
+0.68%
Exelixis Inc stock is traded at $42.70, with a volume of 2.56M.
It is down -0.56% in the last 24 hours and down -3.09% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$42.94
Open:
$42.83
24h Volume:
2.56M
Relative Volume:
0.99
Market Cap:
$11.09B
Revenue:
$2.29B
Net Income/Loss:
$677.90M
P/E Ratio:
17.98
EPS:
2.3753
Net Cash Flow:
$779.77M
1W Performance:
+0.78%
1M Performance:
-3.09%
6M Performance:
+12.52%
1Y Performance:
+30.18%
1-Day Range:
$42.35
$43.52
1-Week Range:
$40.92
$44.28
52-Week Range:
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
42.70 | 11.15B | 2.29B | 677.90M | 779.77M | 2.3753 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis Reports Solid Earnings-Are New Highs Back on the Table? - Finviz
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by LSV Asset Management - MarketBeat
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com India
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com
EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts - Benzinga
Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 - MarketBeat
EXEL: Stifel Raises Price Target to $44 and Maintains Hold Ratin - GuruFocus
Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00 - MarketBeat
Citizens maintains Exelixis stock rating on promising cancer treatment data By Investing.com - Investing.com Canada
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus - Yahoo Finance UK
RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating - marketscreener.com
Citizens maintains Exelixis stock rating on promising cancer treatment data - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight - GuruFocus
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Exelixis Q4 2025 Earnings Call Transcript - MarketBeat
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch - MSN
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics - sharewise.com
Exelixis (EXEL) Reports Strong Q4 2025 Earnings with Robust Grow - GuruFocus
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion By Investing.com - Investing.com South Africa
Exelixis Q4 Earnings Call Highlights - Yahoo Finance
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Upda - PharmiWeb.com
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com
Earnings call transcript: Exelixis Q4 2025 reports EPS beat, stock dips - Investing.com India
Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue - ChartMill
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis: Q4 Earnings Snapshot - KVUE
Why Exelixis (EXEL) is one of the best healthcare stocks under $50 to invest in - MSN
EXEL: Amended Ipsen deal grants exclusive cabozantinib rights outside U.S./Japan, $200M upfront, royalties - TradingView
EXELIXIS, INC. SEC 10-K Report - TradingView
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.62B - marketscreener.com
Exelixis, Inc. Profit Climbs In Q4 - Nasdaq
Exelixis (NASDAQ:EXEL) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS - MarketBeat
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can zanzalintinib justify valuation? - Investing.com
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In - Yahoo! Finance Canada
Stock Report: Will Exelixis Inc outperform its industry peersBreakout Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD - Finviz
Exelixis (EXEL) Poised for Q4 Earnings Announcement - GuruFocus
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN
Can Exelixis Inc. stock sustain institutional interestExit Point & Reliable Volume Spike Alerts - mfd.ru
A Peek at Exelixis's Future Earnings - Benzinga
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup - ChartMill
Exelixis (EXEL) Is Up 6.1% After FDA Accepts Colorectal Cancer Combo NDAWhat's Changed - simplywall.st
Aug Big Picture: What is the earnings history of Exelixis Inc2025 Buyback Activity & Consistent Return Investment Signals - baoquankhu1.vn
Exelixis, Inc. $EXEL Shares Sold by Principal Financial Group Inc. - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Raises Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):